Non-continuous measurement of intraocular pressure in laboratory animals

Millar, J. A.; Pang, Iok‐Hou

doi:10.1016/j.exer.2015.04.018

Cited by 16 publications

(10 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The preclinical assessment of drugs aimed at lowering IOP has been traditionally performed on monkeys with artificially increased IOP (Wang et al, 2000), but such experiments are prohibitively expensive and currently rarely conducted due to ethical reasons. Instead, following the development of non-invasive technologies of IOP measurement applicable to small animals, IOP-dependent rodent models have become popular, in which OH is artificially induced (Millar and Pang, 2015;Biswas and Wan, 2019). Although these models reproduce certain aspects of human glaucoma, since retinal ganglion cell (RGC) loss does not develop naturally, an increase in IOP is usually abrupt and may not be long-lasting, and inflammatory components due to physical injury may be a confounding factor.…”

Section: Introductionmentioning

confidence: 99%

Changes of Ocular Dimensions as a Marker of Disease Progression in a Murine Model of Pigmentary Glaucoma

et al. 2020

View full text Add to dashboard Cite

The elevation of intraocular pressure (IOP), a major risk factor in glaucoma, is an important parameter tracked in experimental models of this disease. However, IOP measurement in laboratory rodents is challenging and may not correlate with some key pathological events that occur in the development of glaucoma. The aims of this study were to quantify changes in ocular morphology in DBA/2J mice that develop spontaneous, age-dependent, pigmentary glaucoma and to check the possible correlation of these parameters with IOP. Method: Eye morphology was evaluated with MRI in DBA/2J, DBA/2J-Gpnmb + /SjJ, and C57BL/6J female mice ages 3, 6, 9, 12, and 15 months. The animals were anesthetized with isoflurane. A planar receive-only surface coil (inner diameter = 10 mm) was placed over each animal's left eye and the image was acquired with a 7T small animal-dedicated magnetic resonance tomograph and T2-weighted TurboRARE sequence. Ocular dimensions were manually quantitated using OsiriX software. IOP was measured with rebound tonometry. Results: In the control animals, no age-related changes in the ocular morphology were noted. Since 6 months of age, the anterior chamber deepening and elongation of the eyeballs of DBA/2J mice was detectable. We found a significant, positive correlation between IOP and axial length, anterior chamber area, or anterior chamber width in C57BL/6J mice but not in DBA/2J mice. However, after excluding the measurements performed in the oldest DBA/2J mice (i.e. analyzing only the animals ages 3 to 12 months), we demonstrated a significant positive correlation between IOP and anterior chamber width. Conclusion: High-resolution magnetic resonance imaging of the eye area in mice enables reproducible and consistent measures of key dimensions of the eyeball. We observed

show abstract

Section: Introductionmentioning

confidence: 99%

Changes of Ocular Dimensions as a Marker of Disease Progression in a Murine Model of Pigmentary Glaucoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[3][4][5] Many reports have confirmed the accuracy of tonometry readings through simultaneous validation with direct cannulation methods, which have been traditionally accepted as the most accurate method of measuring IOP. [6][7][8] Unlike tonometry, direct cannulation studies require the use of an anesthetic agent.…”

Section: Introductionmentioning

confidence: 99%

Differential Intraocular Pressure Measurements by Tonometry and Direct Cannulation After Treatment with Soluble Adenylyl Cyclase Inhibitors

Gandhi

Chowdhury

Manzar

et al. 2017

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Rabbits were treated with care and were maintained calm for at least 3 min before IOP measurement. In the case of any sign of stress, IOP measurements were postponed for at least another 3 min [20,21]. For each eye, IOP was set at 100% with two basal readings taken 30 min before and immediately before the instillation of the formulations.…”

Section: Methodsmentioning

confidence: 99%

Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers

et al. 2019

View full text Add to dashboard Cite

Topical application of drops containing ocular drugs is the preferred non-invasive route to treat diseases that affect the anterior segment of the eye. However, the formulation of eye drops is a major challenge for pharmacists since the access of drugs to ocular tissues is restricted by several barriers. Acetazolamide (ACZ) is a carbonic anhydrase inhibitor used orally for the treatment of ocular hypertension in glaucoma. However, large ACZ doses are needed which results in systemic side effects. Recently, we synthesized copolymers based on 2-hydroxyethyl methacrylate (HEMA) and a functionalized three-arm poloxamer star (Bayfit-MA). The new material (HEMA/Bayfit-MA) was engineered to be transformed into nanoparticles without the use of surfactants, which represents a significant step forward in developing new ophthalmic drug delivery platforms. Acetazolamide-loaded nanocarriers (ACZ-NPs) were prepared via dialysis (224 ± 19 nm, −17.2 ± 0.4 mV). The in vitro release rate of ACZ was constant over 24 h (cumulative delivery of ACZ: 83.3 ± 8.4%). Following standard specifications, ACZ-NPs were not cytotoxic in vitro in cornea, conjunctiva, and macrophages. In normotensive rabbits, ACZ-NPs generated a significant intraocular pressure reduction compared to a conventional solution of ACZ (16.4% versus 9.6%) with the same dose of the hypotensive drug (20 µg). In comparison to previously reported studies, this formulation reduced intraocular pressure with a lower dose of ACZ. In summary, HEMA:Bayfit-MA nanoparticles may be a promising system for ocular topical treatments, showing an enhanced ocular bioavailability of ACZ after a single instillation on the ocular surface.

show abstract

Non-continuous measurement of intraocular pressure in laboratory animals

Cited by 16 publications

References 149 publications

Changes of Ocular Dimensions as a Marker of Disease Progression in a Murine Model of Pigmentary Glaucoma

Changes of Ocular Dimensions as a Marker of Disease Progression in a Murine Model of Pigmentary Glaucoma

Differential Intraocular Pressure Measurements by Tonometry and Direct Cannulation After Treatment with Soluble Adenylyl Cyclase Inhibitors

Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers

Contact Info

Product

Resources

About